Delivering Nanoparticles To Prevent Rupture Of Unstable Arterial Plaques
Funder
National Health and Medical Research Council
Funding Amount
$613,652.00
Summary
The aim of this project is to develop an immune-mediated ‘smart bomb’ concept of drug delivery into atherosclerotic plaques for the prevention of plaque rupture. An overwhelming majority of fatal heart attacks and sudden death all over the world result from plaque rupture; making this research highly important in finding a bio-technologically advanced way of preventing heart attacks and sudden death in patients with coronary artery disease.
Developing Functionalised Microbubbles For Molecular Ultrasound Imaging And Targeted Delivery Of Drugs And MicroRNA Therapeutics
Funder
National Health and Medical Research Council
Funding Amount
$677,229.00
Summary
We aim to develop gas-filled microbubbles that are directed to markers of thrombosis and inflammation and will allow visualisation of blood clots and early inflammatory reactions via ultrasound. This will allow early and timely treatment. We will systematically test for the best method of microbubble coating with recombinant antibodies in various animal models of thrombosis and inflammation. In addition, we plan to load microbubbles with drugs and target these to areas where they are needed.
Translating Science Into Treatment For Ischemic Stroke
Funder
National Health and Medical Research Council
Funding Amount
$431,000.00
Summary
My team has pioneered research in Australia that has advanced knowledge in the delivery of safer and more effective stroke therapies. I have developed software for the automated processing of multimodal CT imaging to better select patients for stroke therapies. In order to move this cutting-edge imaging technology into routine clinical practice several processes will occur: Implementation, validation and demonstration of patient benefits, and cost effectiveness of CT imaging selection in routine
Novel Soluble Guanylate Cyclase Activators For Pulmonary Artery Hypertension
Funder
National Health and Medical Research Council
Funding Amount
$474,087.00
Summary
Pulmonary hypertension (elevated blood pressure in the lungs) is a life-threatening condition with few treatment options. We have recently identified a new class of drug that may improve blood vessel function in the lungs and thereby provide a new drug for the management of this group of patients.
Nanoparticle And Virus Assisted Targeting Of MicroRNA And DNA For The Treatment Of Atherosclerosis, Myocardial Infarction And Other Inflammatory Diseases
Funder
National Health and Medical Research Council
Funding Amount
$663,583.00
Summary
Inflammation is an underling cause or aggravating factor of many diseases, such as heart attack and atherosclerosis, but there is a lack of effective anti-inflammatory drugs that do not cause side effects. Using advanced biotechnology, we will use viruses and nanoparticles to selectively target gene therapeutics to areas of inflammation, resulting in high efficacy with low side effects. We will test these broadly usable therapeutics in mouse models of heart attack and atherosclerosis.
Value-Based Healthcare In Elective Coronary Stenting
Funder
National Health and Medical Research Council
Funding Amount
$1,236,881.00
Summary
Coronary stents are wire mesh tubes inserted into cholesterol blockages in heart blood vessels (arteries) thus improving coronary blood flow and alleviating chest pain. Although life saving in acute heart attacks, their value is limited in stable patients and may be associated with severe complications. In partnership with the health department, this project will evaluate how many patients continue to experience chest pain after elective coronary stenting so that can be used more effectively.
An Investigation Of The Involvement Of Clotting Factors In Abdominal Aortic Aneurysm (AAA) Progression Within A Mouse Model
Funder
National Health and Medical Research Council
Funding Amount
$189,401.00
Summary
Early stage weakening of the main abdominal artery is present in ~100,000 Australians and currently has no accepted therapy. Development of drug therapies which limit progression of the weakening process is urgently needed. In this study involvement of the clotting cascade in artery weakening will be investigated. The study have been planned in order to identify new strategies which can be developed as treatments for artery weakening in patients.
Development Of An Extended Release Oral Formulation Of Milrinone For Patients With Advanced Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$467,083.00
Summary
Heart failure is a debilitating condition associated with frequent hospitalization. Milrinone is an effective intravenous drug used to treat acute deteriorations. Previously, oral milrinone failed because of the lack of availability of appropriate formulations. We have developed an oral formulation which provides stable release of the medication. This application will evaluate the effectiveness of the drug in man and provide the documentation to take the project forward for partnership with indu ....Heart failure is a debilitating condition associated with frequent hospitalization. Milrinone is an effective intravenous drug used to treat acute deteriorations. Previously, oral milrinone failed because of the lack of availability of appropriate formulations. We have developed an oral formulation which provides stable release of the medication. This application will evaluate the effectiveness of the drug in man and provide the documentation to take the project forward for partnership with industry as a means to clinical translation.Read moreRead less
Consumer Navigation Of Electronic Cardiovascular Tools - The CONNECT Study
Funder
National Health and Medical Research Council
Funding Amount
$1,852,716.00
Summary
The CONNECT study will test a new consumer-focussed e-health strategy that provides people with access to personal health information and interactive resources to improve their cardiovascular health. It is linked with the patient's primary health care record. The study will involve 2000 adults over 24 months. If the system is found to be effective, it could provide all Australians with access to better health information, assist them to make more informed health choices and ultimately reduce dea ....The CONNECT study will test a new consumer-focussed e-health strategy that provides people with access to personal health information and interactive resources to improve their cardiovascular health. It is linked with the patient's primary health care record. The study will involve 2000 adults over 24 months. If the system is found to be effective, it could provide all Australians with access to better health information, assist them to make more informed health choices and ultimately reduce death and disability related to chronic diseases.Read moreRead less
Performance And Delivery Of Cardiovascular Health Services
Funder
National Health and Medical Research Council
Funding Amount
$389,860.00
Summary
Heart disease is an important cause of death and disability. The treatments received by patients hospitalised with common heart conditions can vary considerably. At present, there are no systematic methods in place to routinely assess the quality of care or patient outcomes following hospitalisation. This proposal keeps developing quality indicators to measure care experienced by patients admitted following a heart attack or those with heart failure as well for those undergoing common cardiac pr ....Heart disease is an important cause of death and disability. The treatments received by patients hospitalised with common heart conditions can vary considerably. At present, there are no systematic methods in place to routinely assess the quality of care or patient outcomes following hospitalisation. This proposal keeps developing quality indicators to measure care experienced by patients admitted following a heart attack or those with heart failure as well for those undergoing common cardiac procedures.Read moreRead less